The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1418
Lubiprostone (Amitiza) for Opioid-Induced Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved use of lubiprostone (Amitiza) for treatment of opioid-induced constipation in adults with chronic non-cancer pain. The drug was previously approved for chronic idiopathic constipation and irritable bowel syndrome with constipation.1,2

OPIOID-INDUCED CONSTIPATION — Patients develop tolerance to the analgesic and CNS-depressant effects of opioids, but not to constipation, which can be dose-limiting or cause discontinuation of therapy. It is usually treated with laxatives and stool softeners, which have limited efficacy.3 Methylnaltrexone (Relistor), a mu-opioid receptor antagonist that must be given subcutaneously, is FDA-approved for treatment of opioid-induced constipation in patients with advanced illness receiving palliative care; it apparently does not cross the blood-brain barrier and therefore does ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Lubiprostone (Amitiza) for Opioid-Induced Constipation
Article code: 1418c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian